key: cord-0792305-qv9pz8jn
authors: Tanaka, Shiho; Olson, C. Anders; Barnes, Christopher O.; Higashide, Wendy; Gonzalez, Marcos; Taft, Justin; Richardson, Ashley; Martin-Fernandez, Marta; Bogunovic, Dusan; Gnanapragasam, Priyanthi N.P.; Bjorkman, Pamela J.; Spilman, Patricia; Niazi, Kayvan; Rabizadeh, Shahrooz; Soon-Shiong, Patrick
title: Rapid Identification of Neutralizing Antibodies against SARS-CoV-2 Variants by mRNA Display
date: 2022-01-20
journal: Cell Rep
DOI: 10.1016/j.celrep.2022.110348
sha: 71b7fd0586d6696474ff76a807fea0cdee1ea3b6
doc_id: 792305
cord_uid: qv9pz8jn

The increasing prevalence of SARS-CoV-2 variants with the ability to escape existing humoral protection conferred by previous infection and/or immunization necessitates the discovery of broadly-reactive neutralizing antibodies (nAbs). Utilizing mRNA display, we identify a set of antibodies against SARS-CoV-2 spike (S) proteins and characterize the structures of nAbs that recognize epitopes in the S1 subunit of the S glycoprotein. These structural studies reveal distinct binding modes for several antibodies, including targeting of rare cryptic epitopes in the receptor-binding domain (RBD) of S that interacts with angiotensin-converting enzyme 2 (ACE2) to initiate infection, as well as the S1 subdomain 1. Further, we engineer a potent ACE2-blocking nAb to sustain binding to S RBD with the E484K and L452R substitutions found in multiple SARS-CoV-2 variants. We demonstrate that mRNA display is a promising approach for the rapid identification of nAbs that can be used in combination to combat emerging SARS-CoV-2 variants.

The increasing prevalence of SARS-CoV-2 variants with the ability to escape existing 23 humoral protection conferred by previous infection and/or immunization necessitates the 24 discovery of broadly-reactive neutralizing antibodies (nAbs). Utilizing mRNA display, we 25 identify a set of antibodies against SARS-CoV-2 spike (S) proteins and characterize the 26 structures of nAbs that recognize epitopes in the S1 subunit of the S glycoprotein. These 27 structural studies reveal distinct binding modes for several antibodies, including targeting of rare 28 cryptic epitopes in the receptor-binding domain (RBD) of S that interacts with angiotensin-29 converting enzyme 2 (ACE2) to initiate infection, as well as the S1 subdomain 1. Further, we 30 engineer a potent ACE2-blocking nAb to sustain binding to S RBD with the E484K and L452R 31 substitutions found in multiple SARS-CoV-2 variants. We demonstrate that mRNA display is a 32 promising approach for the rapid identification of nAbs that can be used in combination to 33

Introduction 37

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the 38 causative agent of the respiratory disease COVID-19, has resulted in a pandemic that brought the 39 world to a standstill (Zhou et al., 2020) . Next, we analyzed the high-resolution X-ray crystal structure of the SARS-CoV-2 RBD -N-176 612-056 Fab complex ( Figure 4A ). This method was used rather than cryo-EM due to N-612-177 056's lack of binding to intact S trimers ( Figure 4A ; inset). Similar to the donor-derived antibody 178 COVOX-45 (Dejnirattisai et al., 2021) , N-612-056 binds a rare cryptic epitope that is not readily 179 found in the repertoire of antibodies from convalescent donors ( Figure S4 supplemental 180 information). Consistent with observed binding to dissociated S1 protomers by single-particle 181 cryo-EM (data not shown), the N-612-056 cryptic epitope is inaccessible on an S trimer due to 182 steric clashes with the neighboring NTD, and does not overlap with the ACE2 binding site 183 ( Figure 4A and 4B). N-612-056 HC and LC CDR loops participate equally to bury ~890 Å 2 of 184 the RBD epitope surface area that comprises residues 352-357 in the 1 strand, which is part of a 185 structurally conserved 5-stranded RBD -sheet, and residues 457-471 that comprise a disordered 186 loop directly beneath the ACE2 receptor binding ridge ( Figure 4C and 4D) . In addition to N-612-014, we also identified antibody N-612-004, an S1-specific antibody 221 that was mapped to a domain outside of the NTD and RBD (Figure 1 ). Using single-particle 222 cryo-EM, we determined a 4.8Å structure of N-612-004 bound to a dissociated S1 protomer, 223 which revealed recognition of a SD1 epitope ( Figure 5F and Figure S3 supplemental 224 information). Consistent with our library design that varied CDR loops H2, H3 and L3, N-612-225 004 contacts were solely mediated by these three regions, which led to recognition of loops 556-226 563 and 567-69 in the SD1 domain ( Figure 5G ). The epitope for N-612-004 is not accessible on 227 S trimers, which likely explains the lack of N-612-004-like antibodies identified among a 228 repertoire of antibodies found in convalescent plasma ( Figure S4 supplemental information). 229

To assess the relative affinity of RBD-binding nAbs N-612-017 and N-612-056 against a 231 series of variants, BLI was performed using RBD variants B. variants with IC50 of 2-10 µg/mL as expected ( Figure 6C ). 247

The binding affinity of N-612-014 and N-612-004 against the recombinant S1 domain 248 containing B.1.1.7 mutations was tested and it was determined that 69-70del and Y144del on 249 NTD did not affect binding affinity of N-612-014 for S1 whereas these mutations moderately 250 lowered (by about 3-fold) the binding affinity of N-612-004 for S1 ( Figure S5B type of discrepancy is rare, such inter-assay discrepancies have been described previously (Liu et 314 al., 2020) . N-612-014 may require a longer incubation time to reach maximum neutralization 315 because this allows the opportunity for the S trimer to adopt a conformation that is more 316 susceptible to S1 shedding that is promoted by the antibody, thus destabilizing spike; this 317 hypothesis awaits experimental confirmation. 318

The SD1-targeting antibody N-612-004 displayed partial neutralization activity and was 319 only observed in complex with S1 domain dissociated from the spike trimer in cryo-EM. To our 320 knowledge, there have been no reports on SD1-targeting antibodies that display neutralization 321 activity. We also identified the S2-targeting antibody N-612-007 that displayed partial 322 neutralization activity in a live virus neutralization assay and while structural analysis was 323 attempted, we were unable to visualize/characterize an S trimer/N-612-007 complex. nAbs 

Lead contact: Further information and requests for resources and reagents should be directed to 482 and will be fulfilled by C. Anders Olson (anders.olson@immunitybio.com). 483

All expression plasmids generated in this study for CoV proteins, CoV pseudoviruses, human 485 for 1 hour at room temperature. After washing, the immobilized fusion samples were eluted by 532 heat (95°C) and PCR amplified with KOD hot start polymerase (EMD; Cat #71086). Affinity 533 maturation was performed by replacing the wild type CDRs H1, H2, H3, and L3 with synthetic 534 DNA cassettes derived from oligonucleotides doped at 6% (Hutchison et al., 1986) and 535 performing 3-5 rounds of mRNA display as described above. 536 System. Transfected cells were incubated for 30 min at 37℃, 5% CO2 and then resuspended in 573 Efficient Feed A Cocktail -CHO-CD EfficientFeed™ A (ThermoFisher; Cat #A1023401) + 574 0.2% Pluronic F-68 + 1% HT Supplement + 1% L-glutamine -at a density of ~4-6 x 10 6 575 cells/mL. This cell culture was incubated at 37℃ with 5% CO2 and 125 rpm rotation overnight, 1 576 mM Na butyrate was added, and the culture was further incubated at 32℃ with 3% CO2 and 125 577 rpm for 13 more days; during this incubation period, Maxcyte® Feed Cocktail -13.9% CD 578

Hydrolysate, 69.5% CHO CD EfficientFeed™ A, 6.2% Glucose, 6.9% FunctionMax™ Titer 579 Enhancer, 3.5% L-Glutamine -was added at 10% of the culture volume on Days 3 and Day 8. 580

FectoPRO® transfection cell culture medium was centrifuged and filtered through a 0.22 µm 582 filter to remove cells and debris, then loaded onto a HiTrap™ MabSelect SuRe™ column (GE 583

Healthcare Life Sciences; Cat #11003494) on the AKTA Pure system (Cytiva) pre-equilibrated 584 with 10 mM NaPO4 and 150 mM NaCl at pH 7.0. After loading, the column was washed with 10 585 column volumes of the same buffer. The protein was eluted with 100 mM NaOAc, pH 3.6, then 586 immediately neutralized using 2 M Tris pH 8.0. The elution fractions were pooled and dialyzed 587 into 10 mM Hepes and 150 mM NaCl at pH 7.4. 588 

For epitope binning using S1 domain, biotinylated S1 binding mAbs at 25 µg/mL were first 629 loaded on High Precision Streptavidin SAX biosensors (Sartorius; Cat #18-5117) for 10 sec. 3.75 630 µg/mL of recombinant SARS-CoV-2 S1 were used to bind mAb captured on biosensors for 3 631 min and subsequently 10 µg/mL S1 binding mAb were incubated with biosensors to observe 632 binding competition and signal was recorded for 3 min. For epitope binning using S2 domain, 633 recombinant SARS-CoV-2 S2-His-tag at 10 µg/mL was loaded on Anti-Penta-HIS biosensors for 634 1 min. 10 µg/mL of S2 binding mAbs were sequentially incubated with biosensors for 3-5 min to 635 observe binding competition. 636 N-612-004, N-612-014, and N-612- movies by 2 (0.869 Å/pixel). The non-dose-weighted images were used to estimate CTF 739 parameters using Patch CTF in cryoSPARC, and micrographs with poor CTF fits, signs of 740 crystalline ice, and field of views that were majority carbon were discarded. Particles were 741 picked in a reference-free manner using Gaussian blob picker in cryoSPARC (Punjani et al., 742 2017) Initial particle stacks were extracted, binned x4 (3.48 Å/pixel), and subjected to ab initio 743 volume generation (4 classes) and subsequent heterogeneous refinement with all particles. The 744 3D classes that showed features for a Fab-S trimer complex or Fab-S1 protomer were 2D 745 classified to polish particle stacks. The resulting particle stacks were unbinned (0.869 Å/pixel) 746 and re-extracted using a 432 box size, and moved to Relion v3.1 (Zivanov et al., 2018) for 747 further 3D classification. Particles corresponding to distinct states were separately refined using 748 non-uniform 3D refinement imposing C1 symmetry in cryoSPARC and final resolutions were 749 estimated according to the gold-standard FSC (Bell et al., 2016) . 750

To improve features at the Fab-RBD interface, focused, non-uniform 3D local refinement 751 (Table S6 supplemental  774 information). 775

Buried surface area estimates were made using PDBePISA with a 1.4Å probe (Krissinel and 777 Henrick, 2007) . Potential hydrogen bonds were assigned using a distance of <3.6A ̊ (Krissinel 778 and Henrick, 2007) and an A-D-H angle of >90˚, and the maximum distance allowed for a van 779 der Waals interaction was 4.0 Å. Structure figures were made using UCSF Chimera v1.14 780 

using PBS containing 0.5% FBS, then incubated with in-house (from Dr

SARS-CoV-2 nucleocapsid protein (NP) mouse serum at 1:2000 dilution overnight at 4 o C. After 701 three washes of PBS, cells were incubated with goat anti-mouse Alexa Fluor® 647 (Abcam; Cat 702 #ab150115) at a 1:2000 dilution

Control wells including six wells on each plate for no virus and virus-only controls were used

The percent neutralization was calculated as 100 − ((sample of interest − [average of

* 100) using images of wells containing Np-labeled cells 706 collected by a Celigo Imaging Cytometer (Nexcelom Bioscience)

Pseudovirus neutralization assays

Three-fold serially diluted mAbs were incubated with SARS-CoV-2 pseudovirus for 1 710 hour at 37°C. After incubation with 293TACE2 cells for 48 hours at 37°C, cells were washed 711 twice with PBS, lysed with Luciferase Cell Culture Lysis 5X reagent (Promega

and NanoLuc Luciferase activity in lysates was measured using the Nano-Glo Luciferase Assay 713

Relative luminescence units (RLUs) were normalized to values 714 derived from cells infected with pseudovirus in the absence of mAbs. Half-maximal inhibitory 715 concentrations (IC50 values) for mAbs were determined using 4

Fab-S complexes were assembled by incubating 719 purified SARS-CoV-2 S trimer at a 1.1:1 molar excess of purified Fab per S protomer at RT for 720 20 min. Complex was mixed with F-octylmaltoside solution (Anatrace; Cat #0310F) to a final 721 concentration of 0

PHENIX: a comprehensive Python-based 798 system for macromolecular structure solution

Structures of Human

Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of 802 Antibodies

SARS-CoV-2 neutralizing 805 antibody structures inform therapeutic strategies

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid 808 mutational escape seen with individual antibodies

High resolution single particle 810 refinement in EMAN2

Potent neutralizing antibodies from 813 COVID-19 patients define multiple targets of vulnerability

Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput

Single-Cell Sequencing of Convalescent Patients' B Cells

The dual function monoclonal 819 antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro

Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent 823 plasma

Potent SARS-CoV-2 neutralizing antibodies directed against spike N-826 terminal domain target a single supersite

Mosaic nanoparticles elicit cross-reactive 829 immune responses to zoonotic coronaviruses in mice

Protocol and Reagents for Pseudotyping 832

Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays

Estimated transmissibility and impact 835 of SARS-CoV-2 lineage B.1.1.7 in England

The antigenic anatomy of SARS-CoV-2 receptor 838 binding domain

Transmission, infectivity, and 841 neutralization of a spike L452R SARS-CoV-2 variant

Human Monoclonal 843 Antibodies against Highly Conserved HR1 and HR2 Domains of the SARS-CoV Spike Protein Are 844 More Broadly Neutralizing

Features and development of Coot

Spike Receptor-Binding Domain that Escape Antibody Recognition

Mapping mutations to the SARS-CoV-2 RBD that 853 escape binding by different classes of antibodies

Studies in humanized mice and convalescent humans yield a SARS-856

CoV-2 antibody cocktail

SARS-CoV-2 Cell Entry Depends on ACE2 859 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Neutralization of SARS-CoV-2 by Destruction of the 862 Prefusion Spike

A complete library of point 864 substitution mutations in the glucocorticoid response element of mouse mammary tumor virus

Contribution of Variable Domains 867 to the Stability of Humanized IgG1 Monoclonal Antibodies

Biophysical properties of the clinical-stage antibody landscape

The neutralizing antibody

protects against SARS-CoV-2 infection in nonhuman primates

Pre-fusion structure of a human 878 coronavirus spike protein

Inference of Macromolecular Assemblies from Crystalline 880 State

SARS-CoV-2 spike variants exhibit differential infectivity 883 and neutralization resistance to convalescent or post-vaccination sera

Characterization of neutralizing monoclonal antibodies recognizing a 15-887 residues epitope on the spike protein HR2 region of severe acute respiratory syndrome 888 coronavirus (SARS-CoV)

Angiotensin-converting enzyme 2 is a 891 functional receptor for the SARS coronavirus

The human coronavirus HCoV-229E S-protein structure 894 and receptor binding

mRNA Display Design of Fibronectin-based Intrabodies That Detect and

Acute Respiratory Syndrome Coronavirus Nucleocapsid Protein

Monoclonal Antibodies Targeting the HR2 Domain and the Region 901 Immediately Upstream of the HR2 of the S Protein Neutralize In Vitro Infection of Severe Acute 902 Respiratory Syndrome Coronavirus

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. 905

Optimized synthesis of RNA-protein 907 fusions for in vitro protein selection

Automated electron microscope tomography using robust prediction 909 of specimen movements

SARS-CoV-2 immune evasion by the 912 B.1.427/B.1.429 variant of concern

N-terminal domain antigenic mapping reveals a site of 915 vulnerability for SARS-CoV-2

Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody 918 escape

Phaser crystallographic software

In Vitro Selection of 922 Peptides and Proteins-Advantages of mRNA Display

A novel variant of interest of SARS-CoV-2 with 925 multiple spike mutations detected through travel surveillance in Africa

mRNA display antibody library and methods. US 11,015

Modification-Specific Phospho-IκBα-Binding Fibronectin

Rapid mRNA-Display Selection of an IL-6 Inhibitor Using Continuous-Flow 933 Magnetic Separation

Immunogenicity and structures of a rationally 936 designed prefusion MERS-CoV spike antigen

Mapping Neutralizing

Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided 940

Cross-neutralization of SARS-CoV-2 by a human 943 monoclonal SARS-CoV antibody

Spike mutation D614G alters SARS-CoV-2 fitness. 946

cryoSPARC: algorithms for 948 rapid unsupervised cryo-EM structure determination

Adapt or perish: SARS-CoV-2 antibody escape 950 variants defined by deletions in the Spike N-terminal Domain

Convergent antibody responses to SARS-CoV-2 in 954 convalescent individuals

RNA-peptide fusions for the in vitro selection of 956 peptides and proteins

Deep Mutational Scanning of SARS-CoV

Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding

Prospective mapping of viral mutations that escape antibodies used to 963 treat COVID-19

Neutralizing and protective human 966 monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein

mRNA display: ligand discovery, 969 interaction analysis and beyond

Detection of a SARS-CoV-2 variant of concern in 972 South Africa

Cryo-electron microscopy structure of a coronavirus spike glycoprotein 975 trimer

Unexpected Receptor Functional Mimicry Elucidates 978 Activation of Coronavirus Fusion

Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Broad neutralization of SARS-related viruses by 986 human monoclonal antibodies

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with 989 Covid-19

Escape from neutralizing 992 antibodies by SARS-CoV-2 spike protein variants

Bamlanivimab does not neutralize two SARS-CoV-2 995 variants carrying E484K in vitro

Overview of the CCP4 suite and current 998 developments

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus 1004 evolution and furin-cleavage effects

Structural basis of a shared antibody response to SARS-CoV-2

Structural and functional ramifications of antigenic drift in 1010 recent SARS-CoV-2 variants

Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic 1013 receptor binding domains

Structural and Functional Analysis of the 1016 D614G SARS-CoV-2 Spike Protein Variant

A pneumonia outbreak associated with a new coronavirus of probable bat 1019 origin

A protective broadly cross-reactive human antibody defines a conserved 1022 site of vulnerability on beta-coronavirus spikes

New tools for automated high-resolution cryo-EM structure

ELife 7, e42166

Potently neutralizing and protective human antibodies 1028 against SARS-CoV-2

Rapid isolation and profiling of a diverse panel of 1031 human monoclonal antibodies targeting the SARS-CoV-2 spike protein

Five (5) μg antibody samples (1 mg/mL) were spiked in with a mobile phase A solution (1.8 654 M ammonium sulfate and 0.1 M sodium phosphate at pH 6.5) to achieve a final ammonium 655 sulfate concentration of about 1 M before analysis. A Sepax Proteomix HIC butyl-NP5 column 656 (Sepax Tech; Cat #431NP2) on Agilent 1100 HPLC was used with a liner gradient of mobile 657 phase A and mobile phase B solution (0.1 M sodium phosphate, pH 6.5) over 20 min at a flow 658 rate of 1 mL/min with UV absorbance monitoring at 280 nm. Elution time was recorded. 659

Human IgG (Sigma-Aldrich; Cat #I4506) was loaded to an AHQ biosensor (ForteBio) to 661 ∼1 nm, followed by sensor blocking with human IgG1 Fc (R&D Systems; Cat #110-HG). The 662 self-association was performed at 1 μM solution concentration of antibodies for 300s on an Octet 663Red96e system (Sartorius Corporation). The binding response from the association step was 664 subtracted from that of a reference IgG. 665